erdafitinib 3 MG Oral Tablet

RxCUI: 2123131
RxNorm name: erdafitinib 3 MG Oral Tablet
Display name: erdafitinib 3 MG Oral Tablet
Full name: erdafitinib 3 MG Oral Tablet
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:38:51

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
BALVERSA	ERDAFITINIB	Janssen Products LP	2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee	2025-10-24	Warnings, Adverse reactions	Exact identifier rxcui: 2123131

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee	erdafitinib 3 MG Oral Tablet [PSN] · erdafitinib 3 MG Oral Tablet [SCD]	2	14	These highlights do not include all the information needed to use BALVERSA safely and effectively. See full prescribing information for BALVERSA. BALVERSA ® (erdafitinib) tablets, for oral use Initial U.S. Approval: 2019	20251024